USD
Retatrutide, tirzepatide and semaglutide are separate molecular names, not interchangeable labels. This guide distinguishes their public scientific terminology from NOVABIO's catalog fields so readers can identify the correct family, strength and SKU without turning a catalog comparison into medical advice.
Quick definition of each name
Semaglutide is described in the current FDA prescribing information as a glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is described by FDA as a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Retatrutide is described in the published phase 2 paper indexed by PubMed as a triple-hormone-receptor agonist studied at GIP, GLP-1 and glucagon receptors. These descriptions identify different research subjects; they do not establish that a NOVABIO catalog listing is an approved medicine.
Retatrutide vs Tirzepatide vs Semaglutide
| Comparison field | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Public receptor terminology | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist | GIP, GLP-1 and glucagon receptor agonist in the cited phase 2 publication |
| Primary source used here | FDA prescribing information | FDA prescribing information | Peer-reviewed phase 2 paper indexed by PubMed |
| NOVABIO family code | SM | TR | RT |
| What to verify on a product page | Full title, family code, listed strength, package quantity, current price and publication status | ||
Source terminology: FDA semaglutide prescribing information, FDA tirzepatide prescribing information and the retatrutide phase 2 publication indexed by PubMed.
How to compare NOVABIO listings accurately
- Start with the family code. SM, TR and RT point to different product families.
- Read the full compound name. Do not rely on a similar-looking abbreviation or package image.
- Match the listed strength. Compare pages with the same unit and strength rather than assuming that adjacent listings are equivalent.
- Confirm package quantity. The current independent-SKU pages show one listed dose and one package quantity.
- Use the live page for commercial fields. Price, currency, inventory and publication status can change and should be read from the current product page.
Scientific identity and catalog availability are different questions
FDA labels and peer-reviewed publications are cited here only to explain public scientific terminology. They do not verify the identity, purity, suitability or regulatory status of a particular catalog item. NOVABIO product pages should be used for the site's current SKU, package and availability information, while the linked primary sources should be used for the scientific statements attributed to them.
Sources and further reading
Frequently asked questions
Are Retatrutide, Tirzepatide and Semaglutide the same compound?
No. They are distinct names with different receptor terminology in the cited sources. Use the full product title and family code when searching the catalog.
Does this comparison provide dosing or treatment guidance?
No. It is a catalog-identification and terminology guide. It does not recommend a dose, route of administration, treatment or expected outcome.
Where should I confirm the current NOVABIO price and availability?
Use the live product page. Search snippets, screenshots and saved lists can become outdated.